Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents

BACKGROUND: Remimazolam is an ester-based short-acting benzodiazepine currently in clinical trials for IV administration. This study explored the feasibility of delivering remimazolam alone and as an adjunct to remifentanil via inhalation in rodent models. METHODS: Mice were exposed to remimazolam via inhalation; sedation was assessed using time to movement outside a set perimeter. Rats were also exposed to remimazolam aerosol alone and in combination with inhaled remifentanil, and analgesia was quantified by using a tail flick meter. Pulmonary injury was assessed in mice using mechanics measurements. RESULTS: Mice showed significantly increased time to movement outside a set perimeter after 5-minute exposure to increasing concentrations (10–25 mg/mL solutions) of inhaled remimazolam aerosols. Differences in mean (95% confidence interval) time to movement from pretest baseline group (0.05 [0.01–0.09] minutes) were 11 (4–18), 15 (5–26), 30 (19–41), and 109 (103–115) minutes after exposure to remimazolam aerosol of 10, 15, 20, and 25 mg/mL, respectively (P = .007 – P < .0001). Exposure of rats to remimazolam aerosols alone failed to produce sedation or analgesia after a 5-minute exposure. When remimazolam (10 or 25 mg/mL) was administered in combination with 250 &mgr;g/mL remifentanil, there was a significant difference in time to tail flick (P < .0001) consistent with a strong analgesic effect. Mean (95% confidence interval) differences in time to tail flick from the pretest baseline group (3.2 [2.5–3.9] seconds) were 14 (10–18) seconds when 250 &mgr;g/mL remifentanil was administered with either 10 or 25 mg/mL remimazolam. Remimazolam alone or in combination with remifentanil did not cause lung irritation, bronchospasm, or other adverse pulmonary events to the respiratory tract of mice as assessed by Flexi-Vent pulmonary function tests. CONCLUSIONS: Remimazolam can significantly potentiate the analgesic effect of remifentanil when concurrently delivered via inhalation.

[1]  A. Light,et al.  Inhaled Remifentanil in Rodents , 2016, Anesthesia and analgesia.

[2]  M. Rogawski,et al.  Seizure protection by intrapulmonary delivery of midazolam in mice , 2013, Neuropharmacology.

[3]  Gavin Kilpatrick,et al.  A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part I. Safety, Efficacy, and Basic Pharmacokinetics , 2012, Anesthesia and analgesia.

[4]  Gavin Kilpatrick,et al.  A Placebo- and Midazolam-Controlled Phase I Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam (CNS 7056): Part II. Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation , 2012, Anesthesia and analgesia.

[5]  James G. Martin,et al.  Combined forced oscillation and forced expiration measurements in mice for the assessment of airway hyperresponsiveness , 2010, Respiratory research.

[6]  D. Campagnol,et al.  Effects of remifentanil on the minimum alveolar concentration of isoflurane in dogs. , 2010, American journal of veterinary research.

[7]  M. Decramer,et al.  Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. , 2010, American journal of respiratory cell and molecular biology.

[8]  J. Bates,et al.  Acid aspiration-induced airways hyperresponsiveness in mice. , 2009, Journal of applied physiology.

[9]  J. Volckens,et al.  Flexible low-cost system for small animal aerosol inhalation exposure to drugs, proteins, inflammatory agents, and infectious agents. , 2009, BioTechniques.

[10]  Gavin Kilpatrick,et al.  CNS 7056: A Novel Ultra–short-acting Benzodiazepine , 2007, Anesthesiology.

[11]  Ching-Chi Lin.  Noninvasive Method to Measure Airway Obstruction in Nonanesthetized Allergen-Sensitized and Challenged Mice , 2001, Respiration.

[12]  R. Raffa,et al.  Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. , 2000, Life sciences.

[13]  Y. Lai,et al.  Respiratory mechanics and maximal expiratory flow in the anesthetized mouse. , 2000, Journal of applied physiology.

[14]  B. Jamerson,et al.  Remifentanil versus Remifentanil/midazolam for Ambulatory Surgery during Monitored Anesthesia Care , 1997, Anesthesiology.

[15]  P. White,et al.  Interactions between Midazolam and Remifentanil during Monitored Anesthesia Care , 1996, Anesthesiology.

[16]  G. Verleden,et al.  Inhibition of cholinergic neurotransmission in human airways by opioids. , 1992, Journal of applied physiology.

[17]  S. Sapienza,et al.  Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. , 1990, The American review of respiratory disease.

[18]  P. Barnes,et al.  Modulation of cholinergic neurotransmission in guinea‐pig airways by opioids , 1990, British journal of pharmacology.

[19]  Fred E. D'Amour,et al.  A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .